Evaluating CO2 Reactivity to Predict Response to Exposure Therapy for Anxiety Disorders
Official title: Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
Run by University of Texas at Austin · NCT05467683 · Data updated 2026-11-12
This study is testing whether measuring how people react to CO2 can help predict if adults with anxiety disorders will benefit from exposure therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University of Texas at Austin Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | November 2, 2022 |
| Main results expected | December 1, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | June 10, 2026 |
| Trial ID | NCT05467683 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 70 with a primary diagnosis of panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder.
✕Probably not a fit
Patients with a history of bipolar or psychotic disorders, substance use disorders, serious cognitive impairment, or active suicidal ideation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the predictive power of a CO2 challenge as a biomarker for determining the effectiveness of exposure-based therapy in adults with anxiety-related disorders. By evaluating CO2 reactivity in 600 participants diagnosed with conditions such as PTSD, OCD, and various anxiety disorders, the researchers hope to identify those who are likely to benefit from this therapy. The study will incorporate CO2 reactivity into a multivariable model alongside other factors to enhance treatment decision-making. This approach builds on previous research linking orexin system activity to fear extinction deficits.
Why it matters
Potential benefit: If successful, this study could provide a valuable tool for clinicians to better select patients who will respond to exposure-based therapy, potentially reducing suffering and improving treatment outcomes.
How similar studies have gone: While the approach of using CO2 reactivity as a biomarker is innovative, similar studies have shown promise in linking physiological responses to treatment outcomes, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5) * A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS) * Ages 18 to 70 * Willingness and ability to provide informed consent and comply with the requirements of the study protocol. * Proficiency in English (because assessment instruments have only been validated in English) Exclusion Criteria: * A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment. * Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months. * Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke). * Pregnancy or lactation * Ongoing psychotherapy directed toward the primary disorder. * Pharmacological treatment started within 8 weeks prior to the screen (patients "stable" on their medication regimen will be included and their medication status will be included as a variable in the model)
Where it's running
-
Boston University
Boston, Massachusetts, United States Recruiting -
The University of Texas at Austin
Austin, Texas, United States Recruiting
Study contacts
- Principal investigator: Jasper Smits, Ph.D. — The University of Texas at Austin
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the impact of self-help CBT in primary care behavioral health
This study is testing if adding guided self-help therapy to regular mental health care can help patients feel better and improve their daily lives.
-
Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety
This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.
-
Mindful Self-Compassion delivered in person versus by video for anxiety and depression
This project will see if an 8-week Mindful Self-Compassion class delivered in person or by video helps people with anxiety or depression have fewer symptoms.
-
Stepped versus stratified care for anxiety in children and adolescents
This project tests whether starting all 8–17-year-olds with anxiety on online CBT and adding in-person CBT only if needed (stepped care) works as well as assigning online or in-person CBT up front based on clinical complexity (stratified care).
-
Team-delivered exposure-based CBT for children and teens with anxiety and OCD
This test tries three ways of delivering team-based exposure-focused CBT—in-person, by telehealth, or a flexible mix—to see which works best for kids and teens (ages 5–18) with anxiety or OCD.
-
Online cognitive behavioral therapy for children and adolescents with anxiety
This project will test whether an internet-delivered CBT program can help children and teens with anxiety feel less anxious.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.